Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments

Breast Cancer Research and Treatment

Volumn 89, Issue 3, 2005, Pages 265-270

  Achiron, Anat ^a,d   Barak, Yoram ^a   Gail, Mitchell ^b   Mandel, Matilda ^a   Pee, David ^c   Ayyagari, Rajeev ^c   Rotstein, Zeev ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b NATIONAL CANCER INSTITUTE   (United States)

^c INFORMATION MANAGEMENT SERVICES INC   (United States)

^d SHEBA MEDICAL CENTER   (Israel)

Author keywords

Breast cancer; Cancer; Immunomodulatory drugs; Multiple sclerosis

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; IMMUNOLOGICAL ADJUVANT; PEPTIDE;

ARTICLE; BREAST CANCER; CANCER; CANCER INCIDENCE; CANCER RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; IMMUNOMODULATION; ISRAEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICAL SIGNIFICANCE; TIME SERIES ANALYSIS; BREAST TUMOR; COHORT ANALYSIS; INCIDENCE; NEOPLASM; REVIEW; TIME;

ADJUVANTS, IMMUNOLOGIC; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INCIDENCE; INTERFERON-BETA; ISRAEL; MALE; MULTIPLE SCLEROSIS; NEOPLASMS; PEPTIDES; TIME FACTORS;

EID: 18444414597     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-004-2229-4     Document Type: Article

References (29)

1. TH Ottenhoff 1996 Selective modulation of T-cell responses in autoimmunity and cancer Immunol Today 17 54 55
2. Y Tomer Y Sherer Y Shoenfeld 1998 Autoantibodies, autoimmunity and cancer Oncol Rep 5 753 761
3. Shoenfeld Y, Gershwin ME (eds): Cancer and Autoimmunity. Elsevier publications, 2000, pp 19-111.
4. RB Lewis CW Castor RE Knisley GG Bole 1976 Frequency of neoplasia in systemic lupus erythematosus and rheumatoid arthritis Arthritis Rheum 19 1256 1260
5. L Mellemkjaer V Andersen MS Linet G Gridley R Hoover JH Olsen 1997 Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus Arthritis Rheum 40 761 768
6. Y Xu PH Wiernik 2001 Systemic lupus erythematosus and B-cell hematologic neoplasm Lupus 10 841 850
7. AK Rosenthal JK [tmp] McLaughlin G Gridley O Nyren 1995 Incidence of cancer among patients with systemic sclerosis Cancer 76 910 914
8. JJ Canoso AS Cohen 1974 Malignancy in a series of 70 patients with systemic lupus erythematosus Arthritis Rheum 17 383 390
9. M Lopez Dupla M Khamashta V Pintado Garcia P Lavilla Uriol E Valencia Ortega A Gil Aguado 1993 Malignancy in systemic lupus erythematosus: a report of five cases in a series of 96 patients Lupus 2 377 380
10. O Mutru M Laakso H Isomaki K Koota 1985 Ten year mortality and causes of death in patients with rheumatoid arthritis Br Med J 290 1797 1799
11. E Thomas DH Brewster RJ Black GJ Macfarlane 2000 Risk of malignancy among patients with rheumatic conditions Int J Cancer 88 497 502
12. F Wolfe DM Mitchell JT Sibley JF Fries DA Bloch CA Williams PW Spitz M Haga SM Kleinheksel MA Cathey 1994 The mortality of rheumatoid arthritis Arthritis Rheum 37 481 494
13. S Jacobsen P Halberg S Ullman 1998 Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma) Br J Rheumatol 37 750 755
14. GRV Hughes 2001 Lupus patients are protected from cancer Lupus 10 833 834
15. A Achiron Y Barak 2000 Multiple sclerosis-from probable to definite diagnosis: a 7-year prospective study Arch Neurol. 57 974 979
16. IR Cohen 2000 Discrimination and dialogue in the immune system Semin Immunol 12 215 219
17. IV Allen JH Millar MJ Hutchinson 1978 General disease in 120 necropsy-proven cases of multiple sclerosis Neuropathol Appl Neurobiol 4 279 284
18. N Koch-Henriksen H Bronnum-Hansen E Stenager 1998 Underlying cause of death in Danish patients with multiple sclerosis: results from the Danish Multiple Sclerosis Registry J Neurol Neurosurg Psychiatry 65 56 59
19. AD Sadovnick K Eisen GC Ebers DW Paty 1991 Cause of death in patients attending multiple sclerosis clinics Neurology 41 1193 1196
20. R Midgard E Glattre M Gronning T Riise A Edland H Nyland 1996 Multiple sclerosis and cancer in Norway. A retrospective cohort study Acta Neurol Scand 93 411 415
21. H Moller RW Kneller JD Boice JH Olsen 1991 Cancer incidence following hospitalization for multiple sclerosis in Denmark Acta Neurol Scand 84 214 220
22. J Palo J Duchesne J Wikstrom 1977 Malignant diseases among patients with multiple sclerosis J Neurol 216 217 222
23. AK Percy FT Nobrega H Okazaki E Glattre T Hurland 1971 Multiple sclerosis in Rochester, Minn. A 60-year appraisal Arch Neurol 25 105 111
24. H Bronnum-Hansen N Koch-Henriksen E Stenager 2004 Trends in survival and cause of death in Danish patients with multiple sclerosis Brain 127 844 850
25. DS Goodin EM Frohman GP Garmany Jr J Halper WH Likosky FD Lublin DH Silberberg WH Stuart S van den Noort 2002 Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines Neurology 58 169 178
26. CM Poser DW Paty L Scheinberg WI [tmp] McDonald FA Davis GC Ebers KP Johnson WA Sibley DH Silberberg WW Tourtellotte 1983 New diagnostic criteria for multiple sclerosis: guidelines for research protocols Ann Neurol 13 227 231
27. MH Gail 1981 Evaluating serial cancer marker studies in patients at risk of recurrent disease Biometrics 37 67 78
28. DR Cox 1972 Regression models and life tables (with discussion) J Roy Statist Soc B 34 187 220
29. Central Bureau of Statistics, Israel: Census of Population and Housing; Publication No. 1, Population and Households, pp 2-74, table 2.23, 2002.